Novel targeted C3 inhibitor pegcetacoplan for paroxysmal nocturnal hemoglobinuria
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Experimental Medicine"
DOI: 10.1007/s10238-022-00830-3
Abstract: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening acquired blood disease characterized by chronic complement-mediated hemolysis and thrombosis. On May 14, 2021, the US FDA approved a new targeted C3 therapy Empaveli (pegcetacoplan), once called… read more here.
Keywords: paroxysmal nocturnal; nocturnal hemoglobinuria; novel targeted; pegcetacoplan ... See more keywords